The gene delusion
By Philip Ball,
New Statesman
| 06. 10. 2020
The genetic data around human difference is inconclusive – but that does not stop right-wing thinkers such as Charles Murray using it to excuse profound social inequalities.
In February this year, the Downing Street adviser Andrew Sabisky was forced to resign when his incendiary comments on race and genetics from six years earlier came to light. Sabisky had been hired by Boris Johnson’s chief adviser, Dominic Cummings, as part of a drive to recruit “weirdos and misfits”. But one of the most alarming aspects of the Sabisky affair is not that he had written that “There are excellent reasons to think the very real racial differences in intelligence are significantly – even mostly – genetic in origin”; it is that such views are hardly even controversial today among many right-wing thinkers.
Sabisky was just 21 when he made those comments, though neither he nor his would-have-been bosses Cummings and Johnson has said whether they agree with them today. So while Sabisky had added that “whether the politicians will pay any attention is debatable… [although] it would be nice if they did from the standpoint of immigration control”, we can’t be sure that the British government isn’t, on the contrary, paying very close attention indeed as it tells...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...